Overweight (BMI > 25)GLOBENCT07229027
Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.
An observational study of Overweight (BMI > 25) and Obesity & Overweight, run by Medialis Ltd. at 1 site in United Kingdom.
Trial summary
We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Overweight (BMI > 25), Obesity & Overweight
- How many people
- 500 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Nov 2025to Aug 2026
- How long will I take part?
- 60 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with BMI over 25 Healthcare professionals treating patients.
Who may be able to join
- Patient group
- Patient is aged ≥18 years at the time of survey completion.
- Patient has a BMI over 25 (self-reported)
- Patient is willing to participate in all study activities.
- Patient is able to read, write, and converse in English.
- Healthcare professional participant must meet the following criteria for inclusion in the study:
Show all 10Show fewer
- HCP is aged ≥18 years at the time of survey completion.
- HCP is suitably qualified and involved in the healthcare management of patients with a BMI over 25
- HCP is willing to participate in all study activities.
- HCP is able to read, write, and converse in English.
Who cannot join
- A participant who meets any of the following criteria will be excluded from the study:
- Participants do not have the cognitive capacity to provide informed consent.
- Participants with severe co-morbidity that might affect study participation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Online recruitment
Milton Keynes, MK12 5NW
Omolade Allen, +447502228066, omolade@medialis.co.uk
About this study
We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.
Read the detailed description
Despite evidence on the burden of BMI >25, few disease-specific instruments comprehensively capture its multidimensional impact. Existing frameworks often target obesity (BMI ≥30) or patients on pharmacological or surgical therapy. Overweight and extremely obese populations are underrepresented, and economic and psychosocial dimensions are rarely integrated into severity staging.
This study, therefore, aims to systematically evaluate symptoms, comorbidities, HRQoL, and costs across the full spectrum of individuals with BMI >25, excluding those on GLP-1 therapy. Integrating clinician and patient perspectives will support the development of more inclusive severity measures and inform early intervention strategies.
- Conditions
- Overweight (BMI > 25), Obesity & Overweight
- Medical subject headings
- Overweight, Obesity
What is being measured
The primary outcome is the main question the study is designed to answer.
Development of a Disease-Specific Questionnaire
Measured: 2 months
Secondary outcomes (1)
Quality of Life Instrument
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2025
- Study start1 Nov 2025
- Primary completionJul 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overweight (BMI > 25)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 60 Months
Sponsor and investigators
- Lead sponsor
- Medialis Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Principal investigator, Ravi Jandhyala, Medialis Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07229027
- Sponsor's protocol ID
- MED 63
- Acronym
- GLOBE
- Status last verified
- Nov 2025
- First submitted
- 13 Nov 2025
- Last updated
- 14 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.
- ClinicalTrials.gov ID
- NCT07229027
- Acronym / sponsor ID
- GLOBE / MED 63
- Conditions
- Overweight (BMI > 25), Obesity & Overweight
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Medialis Ltd.Industry (pharma, biotech, devices)
- Study start
- 1 Nov 2025 (actual)
- Primary completion
- Jul 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 14 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.
Detailed description
Despite evidence on the burden of BMI >25, few disease-specific instruments comprehensively capture its multidimensional impact. Existing frameworks often target obesity (BMI ≥30) or patients on pharmacological or surgical therapy. Overweight and extremely obese populations are underrepresented, and economic and psychosocial dimensions are rarely integrated into severity staging.
This study, therefore, aims to systematically evaluate symptoms, comorbidities, HRQoL, and costs across the full spectrum of individuals with BMI >25, excluding those on GLP-1 therapy. Integrating clinician and patient perspectives will support the development of more inclusive severity measures and inform early intervention strategies.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 60 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with BMI over 25 Healthcare professionals treating patients.
Key inclusion criteria (10 listed)
- Patient group
- Healthcare professional participant must meet the following criteria for inclusion in the study:
Key exclusion criteria (3 listed)
- Participants do not have the cognitive capacity to provide informed consent.
- Participants with severe co-morbidity that might affect study participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Development of a Disease-Specific Questionnaire
Time frame: 2 months
1 secondary outcome
Quality of Life Instrument
Time frame: 2 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Overweight (BMI > 25)
Active, not recruiting
Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity
Obesity &Amp;Amp;Amp; Overweight, Environmental Exposure
Not yet recruiting
WB-EMS Combined With Nutritional Guidance for a High-Protein Diet on Body Composition, Muscle Function, Psychological and Functional Outcomes in Older Adults With Excess Adiposity
Overweight (BMI > 25), Obesity & Overweight
Enrolling by invitation
AIM-WEIGHT: AI-Guided Microbiome-Targeted Nutritional Intervention for Weight Loss
Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight (BMI > 25)
Recruiting
Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation
Impaired Glucose Regulation, Impaired Glucose Tolerance (Prediabetes)
Active, not recruiting
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
Body Mass Index 25 or Greater, BRCA1 Gene Mutation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Overweight (BMI > 25) and Obesity & Overweight, run by Medialis Ltd. at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Omolade Allen, PhD (+447502228066, omolade@medialis.co.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Development of a Disease-Specific Questionnaire (time frame: 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2025.